The COVID-19 pandemic isn't over. A new variant of the virus, called omicron, is now making its way around the world. This new strain of the virus seems more contagious than the previous ones, but we still have a lot to learn about it. However, these recent developments highlight the importance of vaccines in the fight against COVID-19.
While companies such as Pfizer and Moderna currently dominate the coronavirus-vaccine market, there may be space for newcomers. Two biotechs looking to enter this market are Ocugen (NASDAQ: OCGN) and Novavax (NASDAQ: NVAX). But which of these two vaccine makers is the better buy right now? Let's look into these companies' businesses and decide.
Source Fool.com